Our findings provide preclinical proof-of-concept for the combination treatment of a new orally bioavailable BAX activator, BTSA1.2, and Navitoclax, which may provide a broad therapeutic effect in solid tumors and hematological malignancies. This evidence concerns the gene BAX and hematologic disorder.